Q&A: Sangamo’s Duncan McKay on genomic medicinesWe talk to Duncan McKay, senior vice president and general manager, Europe of Sangamo Therapeutics, about the future Share XQ&A: Sangamo’s Duncan McKay on genomic medicineshttps://pharmaphorum.com/views-analysis-market-access/qa-sangamos-duncan-mckay-on-genomic-medicines/
Kite and Sangamo come together in $3bn cancer gene editing allianceTwo pioneers in the parallel technologies of cell therapy and gene therapy have come together in an ambitious Share XKite and Sangamo come together in $3bn cancer gene editing alliancehttps://pharmaphorum.com/views-analysis-oncology/kite-sangamo-come-together-3bn-cancer-gene-editing-alliance/
No safety concerns so far in Sangamo’s groundbreaking gene-editing trialThe trial of Sangamo’s gene-editing treatment for a rare and debilitating disease has got off to a good Share XNo safety concerns so far in Sangamo’s groundbreaking gene-editing trialhttps://pharmaphorum.com/news/no-safety-concerns-far-sangamos-groundbreaking-gene-editing-trial/
Sangamo and new gene therapy partner Pfizer lifted by FDA fast trackSangamo Therapeutics has been granted a fast track designation from the FDA for SB-525, its gene therapy candidate Share XSangamo and new gene therapy partner Pfizer lifted by FDA fast trackhttps://pharmaphorum.com/news/sangamo-new-gene-therapy-partner-pfizer-lifted-fda-fast-track/
